IVD markets grow faster where there is a need for cost-reduction and outcome improvement. This is true with sepsis. This does not mean every new

MA-based Nova Biomedical and its blood analyzers and handheld meter-and-strip systems will be purchased by osmometer and bioprocessing expert Advanced Instruments. The reported $2.2 billion-dollar